A recent study introduced a peptide-drug conjugates (PDCs)-based nanoplatform designed to enhance microglial function by restoring the mTOR-HIF-1α pathway, particularly in later stages of AD pathology [306]. Here, HIF1A is linked to Alzheimer disease.